Cancer Genomics
Articles tagged with Cancer Genomics
New marker aids diagnosis for aggressive prostate cancer
UT MD Anderson shares latest research breakthroughs
Study may help predict response to chemotherapy in triple-negative breast cancer
City of Hope researchers to share new immunotherapy and precision medicine insights across cancer types at ASCO 2026
At ASCO 2026, City of Hope experts will present research on innovative treatments for various types of cancer. Their findings include the efficacy and safety of immunotherapy combinations, as well as the potential use of CBM588 to enhance immune checkpoint blockade in metastatic renal cell carcinoma.
Announcing the 2026 Laureates of the Blavatnik Awards for Young Scientists in Israel
Three young scientists in Israel have been awarded the prestigious Blavatnik Awards for their innovative research in chemistry, cancer biology, and astrophysics. Sergey Semenov, Uri Ben-David, and Paz Beniamini will each receive US$100,000 to advance their projects on complex materials, cancer treatments, and extreme cosmic events.
Researchers identify how enzyme affects infertility and cancer progression
A specific region of Dicer must be activated to achieve proper cell division and reproduction, a discovery that sheds light on the regulation of this enzyme's critical role in both cancer biology and fertility. This finding opens new avenues for studying how small epigenetic changes contribute to disease.
UT MD Anderson establishes Center for Cellular Language Intelligence with $10 million gift from Peggy and Carl Sewell
The Center for Cellular Language Intelligence will decipher the complex communications that govern tumor ecosystems, revealing principles of cellular organization and biological programs influencing cancer initiation and response. Led by Linghua Wang, the center aims to accelerate discovery and deliver new therapeutic targets, predicti...
Unravelling the evolution of leukemia in children with Down Syndrome
Researchers have identified a single genetic change that drives the development of myeloid leukaemia in children with Down Syndrome. The study reveals a common vulnerability and treatment target, suggesting potential repurposed treatments. The genetic change, related to the GATA1 gene, is present at all stages of the disease.
AACR: Zedoresertib and lunresertib combination shows promising antitumor activity
The Phase I MYTHIC trial demonstrated a strong synergy between zedoresertib and lunresertib, showing durable regressions and consistent tumor shrinkage in patients with ovarian cancer. The combination achieved an overall disease control rate of 68.5% and a molecular response rate of 47%.
CRISPR variant selectively targets tumor DNA
Researchers identified a CRISPR variant that distinguishes tumor DNA from healthy DNA and selectively cuts the former. This method relies on methyl groups attached to DNA, which are altered in cancer cells.
Large DRUP-trial sheds light on hidden potential of existing cancer drugs
A large DRUP trial reveals that existing targeted cancer therapies can deliver profound and durable benefits, even in heavily pretreated or rare cancers. About one-third of patients responded to treatment or had stable disease for at least four months.
Cancer Dependency Map Consortium launches Phase 3 to accelerate next-generation therapeutics
The Cancer Dependency Map Consortium is launching Phase 3 to expand its research beyond cancer vulnerabilities to investigate resistance and surface targets. The consortium aims to develop novel oncology targets and biomarkers for the next generation of cancer therapies.
A lung cancer that changes its identity may be hiding in plain sight
A new study maps how rare mixed tumors evolve into hybrid cell states and immune-protected neighborhoods, pointing to new ways to detect and treat combined small-cell lung cancer. The findings reveal that these tumors do not arise from two separate cancers but rather from a single ancestral cell that evolves over time.
New sequencing method exposes hidden gaps in immune signaling
Researchers have developed a new single-cell technology called CIPHER-seq that captures the timing of cytokine activity with greater accuracy. This allows for a clearer view of immune cell behavior and strengthens the foundation for understanding cancer, inflammation, and treatment resistance.
Prioritizing potentially cancer-causing mutations in real-world cancer genomics
A framework has been developed to identify candidate pathogenic variants hidden among uncertain significance variants detected in comprehensive genomic profiling. The framework was tested using BRCA1 and BRCA2 genes, leading to the classification of a previously unknown variant as pathogenic.
Chaos in lymph nodes promotes cancer
Researchers find that rare stromal cells are responsible for maintaining immune cell organization in healthy lymph nodes. However, in aggressive lymphomas, this process breaks down due to a self-reinforcing inflammatory cycle, leading to tissue collapse and poorer outcomes.
New computational biology tool automates and standardizes genome sequencing analysis
A new tool, metapipeline-DNA, automates and standardizes genome sequencing analysis, reducing the complexity of large and complicated data. The open-access resource, developed by Sanford Burnham Prebys and the University of California Los Angeles, aims to improve collaboration and reproducibility across research labs.
New alliance clinical trial aims to improve outcomes in brain tumors
A new clinical trial will investigate whether adding the oral medication vorasidenib to standard chemotherapy improves progression-free survival for people with newly-diagnosed, grade 3 IDH-mutant astrocytoma. The study aims to recruit 400 individuals with this type of brain cancer and evaluate the safety and side-effect profile of the...
Senolytic therapy of PDAC
Researchers explored using CDK4/6 inhibitors to treat PDAC by targeting RB1, which is often inactivated by oncogenic KRAS. This approach showed promise in inducing cellular senescence, but further combination therapy is needed for therapeutic benefit.
Alliance for Clinical Trials in Oncology highlights new and open colorectal cancer trials in March
The Alliance for Clinical Trials in Oncology is spotlighting new trials for colorectal cancer in March, focusing on early detection methods and treatments for treatment delays and loss of appetite. The trials aim to improve patient outcomes, with several enrolling patients with newly diagnosed colon or rectal cancer.
Overcoming ovarian cancer’s resistance to immunotherapy
A new study demonstrates that blocking a signaling protein called FAK helps mobilize an anti-tumor immune response, allowing tumor-fighting cells to approach tumors and shift the behavior of other immune cells to work against them. This approach achieved the best effects on immune cell recruitment, tumor size reduction, and survival ti...
Household cat could hold the key to understanding breast cancer
A study analyzing tumours from almost 500 pet cats identified genetic changes that could help treat breast cancer in humans and animals. Similarities were found between feline mammary cancers and human breast cancers, suggesting potential avenues for therapy.
Cats could hold new keys to human cancer
Researchers analyzed tumour samples from almost 500 domestic cats across five countries, identifying specific driver genes that lead to cancer development. The study found similarities between cat and human cancers, including a common driver gene associated with worse prognosis in humans.
JMIR Publications’ JMIR Bioinformatics and Biotechnology invites submissions on Bridging Data, AI, and Innovation to Transform Health
The journal explores the convergence of computational biology, artificial intelligence, and healthcare innovation, with a focus on precision medicine and enhanced patient care. Submissions are accepted from researchers, clinicians, and technologists on topics such as AI in medicine, computational genomics, and drug discovery.
Discovery of unique brain tumor subtypes offers hope for targeted glioma therapies
Researchers have identified three unique subtypes of mismatch repair deficient high-grade gliomas, providing a clearer understanding of their development and behavior. The findings are helping guide more precise therapies and offer hope for a potential vaccine to target cancer cells earlier.
Randomized trial finds drug therapy reduces hot flashes during prostate cancer treatment
A national clinical trial found that oxybutynin significantly reduced hot flash frequency and quality of life for men undergoing hormone therapy for prostate cancer. The study showed substantial improvements in hot flash symptoms, often within the first week of treatment.
Researchers identify novel RNA linked to cancer patient survival
A recent study published in PNAS reveals a novel non-coding RNA molecule, CUL1-IPA, that regulates key cellular functions and supports the structural integrity of the nucleolus. The discovery suggests this molecule may influence patient survival in certain blood cancers.
Cancer’s super-enhancers may set the map for DNA breaks and repair: A key clue to why tumors become aggressive and genetically unstable
Researchers found that cancer's powerful genetic on switches, called super-enhancers, drive intense gene activity, causing DNA breaks and stress. This can lead to accumulation of mutations over time, fueling cancer's evolution.
Potential tumor-suppressing gene identified in pancreatic cancer
The study reveals that low levels of CTDNEP1 drive early and deadly pancreatic tumors, highlighting its role as a tumor suppressor. Tumors with low CTDNEP1 expression showed stronger metabolic activity and immune evasion.
Changes in genetic structure of yeast lead to disease-causing genomic instabilities
Researchers from The University of Osaka discovered that loss of heterochromatin can trigger genetic changes leading to chromosomal rearrangements and diseases like cancer. Accumulation of R-loops at pericentromeric repeats was found to be a key mechanism in this process.
A study by CNIO identifies new genes that predispose an individual to pancreatic cancer
A new study by CNIO has identified two genes in the complement system that increase the risk of pancreatic ductal adenocarcinoma. These genes, FCN1 and PLAT, may serve as biomarkers for screening high-risk populations.
Children’s Hospital of Philadelphia researchers develop novel approach for guiding immunotherapies toward treating “cold” tumor cells
Children's Hospital of Philadelphia researchers have developed a method to help cancer immunotherapies reach 'invisible' tumors. HLA-Shuttle is an engineered protein complex that restores antigen presentation in immunologically 'cold' neuroblastoma cells, identifying previously unknown targets across 30 genes linked to neuroblastoma.
Fox Chase Cancer Center and Arima Genomics partner to advance 3D genome diagnostics for cancer care
The partnership enables Fox Chase to implement clinical testing utilizing Arima's 3D-genomics technology for multiple tumor types, guiding diagnosis and treatment. This collaboration accelerates innovation through strategic partnerships integrating basic science, clinical research, and patient care.
Personalizing cancer treatments significantly improve outcome success
A clinical trial by UC San Diego School of Medicine found that personalizing cancer treatments using molecular testing improves treatment success. The study used advanced genomic sequencing to identify unique tumor DNA profiles and developed personalized treatment plans, resulting in better treatment results for patients.
New software sheds light on cancer’s hidden genetic networks
Researchers developed RNACOREX, a new open-source software tool that identifies gene regulation networks in cancer. The tool analyzes thousands of molecules simultaneously to detect key interactions, providing an interpretable molecular map that improves understanding of tumors.
Korea University researchers develop ultrasensitive method to detect low-frequency cancer mutations
The MUTE-Seq method detects rare cancer mutations at exceptionally low frequencies, enriching circulating tumor DNA and improving detection accuracy. It increases variant allele frequencies by tens of times, enabling detection of mutations present at 0.005% or lower.
MD Anderson shares latest research breakthroughs
Researchers at MD Anderson have made significant discoveries in the treatment of rare bile duct cancers, with zanidatamab showing promising results. Additionally, a study identified RASH3D19 as a target to overcome treatment resistance in KRAS-mutant cancers.
Study provides comprehensive insights into DNA language models
A study compares five DNA foundation language models across 57 diverse datasets to identify their strengths and weaknesses in predicting gene expression, identifying genomic components, and detecting harmful mutations. The findings highlight the importance of selecting appropriate models based on specific genomic tasks.
UTEP researcher finds potential new treatment for aggressive ovarian cancer
A UTEP research team found that Claudin-4, a protein increasing in ovarian cancer, may help tumors survive and hide from the immune system. Targeting Claudin-4 with a peptide and PARP inhibitor slows tumor growth and enhances the immune system's ability to fight cancer.
Study uncovers hidden class of BRCA1 mutations and a potential way to target them
Researchers have discovered a new class of BRCA1 mutations that can be targeted by HSP90 inhibitors, potentially improving treatment outcomes for patients with breast cancer. The study found that these mutations are more resistant to PARP inhibitor treatment but can be overcome with low-dose HSP90 inhibition.
CRISPR breakthrough reverses chemotherapy resistance in lung cancer
Researchers have shown that disabling the NRF2 gene with CRISPR technology can restore drug sensitivity and slow tumor growth in lung cancer. The approach, which targets a master switch for resistance, has potential across multiple tumor types.
Launch of provincial hereditary cancer registry to drive new discoveries and link Ontarians to resources
The Ontario Hereditary Cancer Research Network has created a comprehensive provincial database to support research on cancers passed down through genetics. Ontarians at risk of hereditary cancers can now register for access to clinical trials, advocacy groups, and other resources.
Computational deep dive surfaces unexplored world of cancer drug targets
A new computational tool called DeepTarget predicts direct and indirect targets of cancer drugs, revealing that small molecules can have different targets and effects depending on the disease and cell type. The study demonstrates the tool's superior performance in real-world scenarios, highlighting its potential to accelerate drug deve...
Mystery of treatment-resistant childhood leukemia uncovered
Researchers identified a new subtype of T-cells that do not respond to current treatments and could impact clinical care. A genetic marker, ZBTB16, was found to be switched on in these cells, which can be used to identify them.
Genetic testing trifecta predicts risk of sudden cardiac death and arrhythmia
A new genetic risk score combines rare and common gene variants with non-coding genome information to predict arrhythmia risk. This comprehensive framework can be applied to other genetically influenced diseases like cancer and Parkinson's Disease.
Signpost of cancer linked to wound-healing properties
Researchers at Arizona State University discovered that SerpinB3 plays a natural role in the body's wound-healing process, helping skin recover after damage. The protein helps activate keratinocytes to rebuild tissue and improve skin strength.
Student's unexpected rise as a researcher leads to critical new insights into HPV
A University of Delaware student's unexpected rise as a researcher led to critical new insights into human papillomavirus (HPV) and its role in cancer. The study found that specific mutations in HPV proteins may increase cancer risk, paving the way for improved approaches to diagnosing and treating HPV-related cancers.
New Cleveland Clinic research finds up to 5% of Americans carry genetic mutations associated with cancer risk
Up to 17 million people in the US, approximately 5%, carry genetic mutations associated with cancer risk. The study highlights the importance of routine cancer screenings and suggests expanding genetic testing beyond high-risk groups.
Decoding the T-cell burst: Signature genes that predict T-cell expansion in cancer immunotherapy
Researchers at Tokyo University of Science identified genes that predict CD8+ T cell expansion in cancer immunotherapy. A 'signature gene set' or 'expansion signature' was found to identify primed T cells for growth, predicting treatment response and offering a potential guide for new therapies.
The Josep Carreras Institute, at the forefront of spatial biology
The Josep Carreras Institute is pioneering Spatial Transcriptomics to understand tumor structure at the cellular level. The institute's guidance on this methodology offers practical solutions for improving reproducibility and clinical application.
The Gabriella Miller Kids First Data Resource Center (Kids First DRC) has launched the Variant Workbench
The Variant Workbench enables researchers to explore genetic data in a single, integrated workspace, linking genomic information with clinical conditions. By reducing data complexity, the tool facilitates scientific discovery and accelerates pace of research.
New study links genetic variation to chemotherapy-related liver damage in patients with colorectal cancer liver metastases
Researchers at Mayo Clinic identified a genetic factor contributing to severe liver damage after chemotherapy for colorectal cancer patients. A specific gene variant, PNPLA3, was linked to increased risk of liver injury.
Study identifies candidates for therapeutic targets in pediatric germ cell tumors
Researchers have identified distinct immune profiles for different subtypes of pediatric germ cell tumors, which could lead to more targeted therapies. The study found that certain tumor subtypes respond well to immunotherapy and others exhibit an immunosuppressive environment, making them more aggressive.
Southampton-led team to develop next-gen cancer treatments
A consortium led by the University of Southampton aims to advance cutting-edge treatments for lung cancer, blood cancers, and chronic inflammation. The ON-TRACT project will train researchers in academic, industrial, and clinical settings to develop safer and more effective treatments.
‘Rogue’ DNA rings reveal earliest clues to deadly brain cancer’s growth
A team of scientists has identified rogue DNA rings as early drivers of glioblastoma growth, suggesting a window of opportunity for earlier detection and treatment. The study suggests that targeting these DNA rings could lead to more effective treatments.
First-ever clinical trial demonstrates safety, molecular readout and promise of pre- and post-surgery immunotherapy combination for patients with operable mesothelioma
A new study demonstrates the safety and potential benefits of a perioperative combination immune checkpoint blockade in resectable mesothelioma. Patients treated with the regimen lived a median of 28.6 months, with nearly 36% alive and recurrence-free at follow-up.
MD Anderson research highlights for September 5, 2025
Researchers at MD Anderson have made significant advancements in treating kidney cancer, including the use of metastasis-directed targeted radiation therapy to delay systemic treatments. Additionally, preliminary data from an ELI-002 vaccine trial showed promise in delaying relapse of KRAS-mutated pancreatic and colorectal cancers.
DNA analysis shows colorectal cancer has unique microbial fingerprint
Researchers found a unique microbial signature in colorectal cancer samples that can accurately distinguish them from other types of cancer. This discovery has the potential to improve diagnosis and treatment outcomes for patients with colorectal cancer.
Damon Runyon Cancer Research Foundation awards $4.8 million to exceptional early-career scientists
The foundation provides $300,000 total funding over four years to investigate cancer causes, mechanisms, therapies, and prevention. This support fosters interdisciplinary research and encourages innovative projects that push boundaries and make breakthroughs.